OasisLMS

Upon completion of this activity, participants should be able to:

• Outline the optimal approach to immunosuppression after liver transplant
• Identify how to evaluate and manage biliary tract complications in the allograft
• Identify the key recommendations for the use of hepatitis C and hepatitis B infected organs
• Describe appropriate follow-up of patients transplanted for alcohol-related liver disease

The American Association for the Study of Liver Diseases is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Association for the Study of Liver Diseases designates this enduring material activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This online educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence for Accredited Continuing Education by members of the AASLD Transplant Hepatology Board Review Course faculty, the AASLD Maintenance of Certification Committee and the AASLD Governing Board. As an accredited provider, AASLD must collect information from all planners, faculty and others in the planning and control of continuing medical education (CME) activities to disclose all of their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the education.

The American Association for the Study of Liver Diseases (AASLD) has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. Conflicts, if any, are resolved through one or more processes. All relevant conflicts pertaining to this activity have been mitigated.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Andrew Keaveny, MD, FRCPI, FAASLD
Scientific Consultant/Advisor: Mallinckrodt Pharmaceuticals, BioVie
Grant/Research Support: HepQuant LLC, BioVie, Regeneron Pharmaceuticals, Gabriel House of Care, River 2 Renal Company
Intellectual Property Rights: UpToDate

Helen Te, MD, FAASLD
Grant/Research Support: European Foundation for the Study of Chronic Liver Failure

Tom Schiano, MD, FAASLD
Scientific Consultant/Advisor: Eurofins Transplant Genomics
Grant/Research Support: Trugraf

https://www.aasld.org/terms-use-and-privacy-policy